These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 26404261)

  • 1. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S; Mukherji D; Shamseddine A
    Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.
    Daley BR; Vieira HM; Rao C; Hughes JM; Beckley ZM; Huisman DH; Chatterjee D; Sealover NE; Cox K; Askew JW; Svoboda RA; Fisher KW; Lewis RE; Kortum RL
    Proc Natl Acad Sci U S A; 2023 Nov; 120(47):e2313137120. PubMed ID: 37972068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
    Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J
    Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
    Faber AC; Coffee EM; Costa C; Dastur A; Ebi H; Hata AN; Yeo AT; Edelman EJ; Song Y; Tam AT; Boisvert JL; Milano RJ; Roper J; Kodack DP; Jain RK; Corcoran RB; Rivera MN; Ramaswamy S; Hung KE; Benes CH; Engelman JA
    Cancer Discov; 2014 Jan; 4(1):42-52. PubMed ID: 24163374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in
    Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J
    Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer.
    Zheng YN; Lou SY; Lu J; Zheng FL; Tang YM; Zhang EJ; Cui SL; Zhao HJ
    Cell Death Dis; 2024 Jul; 15(7):474. PubMed ID: 38956060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
    Leiphrakpam PD; Are C
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF-Directed Therapy in Metastatic Colorectal Cancer.
    Korphaisarn K; Kopetz S
    Cancer J; 2016; 22(3):175-8. PubMed ID: 27341594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BRAF pathway in low-grade serous ovarian cancer.
    Perrone C; Angioli R; Luvero D; Giannini A; Di Donato V; Cuccu I; Muzii L; Raspagliesi F; Bogani G
    J Gynecol Oncol; 2024 Jul; 35(4):e104. PubMed ID: 38768941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.
    Catalanotti F; Solit DB; Pulitzer MP; Berger MF; Scott SN; Iyriboz T; Lacouture ME; Panageas KS; Wolchok JD; Carvajal RD; Schwartz GK; Rosen N; Chapman PB
    Clin Cancer Res; 2013 Apr; 19(8):2257-64. PubMed ID: 23444215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer.
    Yang H; Xiao X; Zeng L; Zeng H; Zheng Y; Wang J; Li G; Dai W; He Y; Wang S; Peng J; Chen W
    J Transl Med; 2024 Feb; 22(1):132. PubMed ID: 38310289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway.
    Kidger AM; Sipthorp J; Cook SJ
    Pharmacol Ther; 2018 Jul; 187():45-60. PubMed ID: 29454854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.
    Adamopoulos C; Papavassiliou KA; Poulikakos PI; Papavassiliou AG
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the multifaceted BRAF in cancer: New directions.
    Toye E; Chehrazi-Raffle A; Hwang J; Antonarakis ES
    Oncotarget; 2024 Jul; 15():486-492. PubMed ID: 39018217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.
    Kim JE; Stones C; Joseph WR; Leung E; Finlay GJ; Shelling AN; Phillips WA; Shepherd PR; Baguley BC
    BMC Cancer; 2012 Apr; 12():141. PubMed ID: 22475322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
    Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW
    Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting mTOR network in colorectal cancer therapy.
    Wang XW; Zhang YJ
    World J Gastroenterol; 2014 Apr; 20(15):4178-88. PubMed ID: 24764656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exceptional Response of
    Kerle IA; Scheuble AM; Kobitzsch B; Stocker G; Hiller GGR; Badendick M; William D; Krueger A; Gross T; Koegler A; Hartig A; Richter D; Aust DE; Schroeck E; Heining C; Glimm H; Hacker UT
    JCO Precis Oncol; 2024 May; 8():e2400030. PubMed ID: 38820503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
    Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
    J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of BRAF and mTOR in
    Sen S; Tanaka R; Khatua S; Zaky W; Janku F; Penas-Prado M; Weathers SP; Behrang A; Roszik J; Subbiah V
    Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.